

(c) a foreign DNA carried in *E. coli* JM109 (3D9) (deposit number FERM BP-6929), and

C₁ (d) a DNA which hybridizes with a DNA of any one of (a) to (C) under "stringent hybridization" conditions wherein said DNA encodes a tumor antigen protein which gives rise to tumor antigen peptide(s) that bind(s) to an HLA antigen and are recognized by cytotoxic T lymphocytes.

7. (Amended) A pharmaceutical composition that comprises as an active ingredient the protein of claim 6.

#2/32 8. (Amended) A pharmaceutical composition for treating or preventing tumors, which comprises as an active ingredient the protein of claim 6.

101 9. (Amended) A tumor antigen peptide that is a "partial peptide" derived from the protein of claim 6, and that binds to an HLA antigen and is recognized by cytotoxic T lymphocytes, or a ^{WB} _{WB} "derivative" thereof having functionally equivalent properties.

C₂ 17. (Twice Amended) A pharmaceutical composition for treating or preventing tumors, which comprises as an active ingredient at least one of substances selected from the tumor antigen peptides and "derivatives" thereof according to any one of claims 9 to (16).

object

C₃ 19. (Amended) A recombinant polypeptide obtainable by expressing a recombinant DNA comprising at least one of DNAs that encode the tumor antigen peptides or ^{wd}"derivatives" thereof according to any one of claims 9 to (16). ^{obj}et

20. (Amended) A pharmaceutical composition for treating or preventing tumors, which comprises as an active ingredient the recombinant polypeptide of claim 19.

C₄ 28. (Twice Amended) A diagnostic agent for tumors, which comprises the tumor antigen peptide or ^{obj}"derivative" thereof according to any one of claims 9 to (16) or the protein of claim 6.

✓
Please add the following claims:

C₅ 29. (New) A diagnostic agent for tumors, which comprises the recombinant polypeptide of claim 19.